<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822029</url>
  </required_header>
  <id_info>
    <org_study_id>2006-005678-36</org_study_id>
    <nct_id>NCT00822029</nct_id>
  </id_info>
  <brief_title>Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-walking Children With Cerebral Palsy</brief_title>
  <official_title>Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-walking Children With Cerebral Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Department of Clinical Research and Innovation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a double blind randomized study aiming at estimating the efficiency of oral&#xD;
      bisphosphonates on the decrease of osteoporosis by comparing the evolution of densitometric&#xD;
      values between two groups of children (treatment versus placebo).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In non walking children with cerebral palsy, osteoporosis is responsible for bone pains and&#xD;
      iterative fractures. Classical treatments include physiotherapy, assisted verticalisation by&#xD;
      orthesis and correct feeding with vitamin D and calcium supplementation. Yet this isn't&#xD;
      always sufficient and isn't always possible.&#xD;
&#xD;
      Bisphosphonates, which have been used for years in the treatment of post-menopausic&#xD;
      osteoporosis or of osteogenesis imperfecta in children, can turn out to be very useful for&#xD;
      non-walking children with cerebral palsy.&#xD;
&#xD;
      Studies have been published since 1994 in this indication with encouraging results. Cyclic&#xD;
      intravenous administration of bisphosphonates every 3 months showed an objective increase in&#xD;
      bone density and a decrease in pains and fractures after one year of treatment. Cyclic&#xD;
      intravenous administration nevertheless requires the use of an implanted chamber and&#xD;
      iterative hospitalizations. Oral administration should allow to treat these children, who&#xD;
      already have many treatments, in a simpler way.&#xD;
&#xD;
      The study will concern 40 non-walking children with cerebral palsy aged over 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    only 2 patients inclued and Study Principal Investigator has left the hospital&#xD;
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the efficiency of oral bisphosphonates on the decrease of osteoporosis assessed by osteodensitometry.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the improvement of the biological and clinical consequences (bone pains and fractures) of osteoporosis. To estimate the improvement of the quality of life To estimate the tolerance of oral bisphosphonates.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOSAMAX (oral bisphosphonate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLACEBO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOSAMAX</intervention_name>
    <description>patient receiving one tablet (oral use) 70 mg Fosamax by week</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>patient receiving one tablet (oral use) placebo by week</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  non-walking children with cerebral palsy&#xD;
&#xD;
          -  weight &gt; to or = 20 kg&#xD;
&#xD;
          -  aged between 10 to 18 years old&#xD;
&#xD;
          -  with a Z-score (spinal and / or femoral) &lt;-2 DS&#xD;
&#xD;
          -  with a good dental status&#xD;
&#xD;
          -  capable of holding the seated or half seated position for 30 minutes&#xD;
&#xD;
          -  capable of filling the study questionary&#xD;
&#xD;
          -  with negative blood pregnancy tests on inclusion for pubescent girls&#xD;
&#xD;
          -  Using valid contraception means (condoms, oral contraception) for pubescent girls for&#xD;
             the whole study duration and 6 months after the end of the study&#xD;
&#xD;
          -  affiliated to the social security regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of spine arthrodesis with osteosynthesis&#xD;
&#xD;
          -  gastro-oesophageal reflux&#xD;
&#xD;
          -  oesophagal disease or any factor leading to a delaying or slowing the oesophagal&#xD;
             transit (such as stenosis or achalasy)&#xD;
&#xD;
          -  severe difficulties in swallowing&#xD;
&#xD;
          -  renal failure&#xD;
&#xD;
          -  history of uveitis&#xD;
&#xD;
          -  hypersensibility to alendronate or to one of its excipients (microcristalline&#xD;
             cellulose, lactose anhydre, croscarmellose sodium, magnesium stearate)&#xD;
&#xD;
          -  deficiency in calcium or in vitamine D&#xD;
&#xD;
          -  calcium malabsorption&#xD;
&#xD;
          -  hereditary galactose intolerance, congenital galactosemia, glucose and galactose&#xD;
             malabsorption syndrome&#xD;
&#xD;
          -  evolutive affection of the upper gastro-intestinal tract such as dysphagia (other than&#xD;
             neurological), gastritis, duodenitis, gastro-duodenal ulcers (or with history of&#xD;
             ulcers in the previous year), evolutive gastro-intestinal bleeding or history of&#xD;
             surgery of the upper gastro-intestinal tract (gastrostomy in particular)&#xD;
&#xD;
          -  history of necrosis of the maxillar bone or of uncovering of the bone or of&#xD;
             cicatrisation delay after a dental surgery&#xD;
&#xD;
          -  emancipated minor&#xD;
&#xD;
          -  prior treatment with bisphosphonates&#xD;
&#xD;
          -  inclusion in another clinical research study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques GRIFFET, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chirurgie Infantile - HÃ´pital ARCHET</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <last_update_submitted>March 23, 2012</last_update_submitted>
  <last_update_submitted_qc>March 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Nice</investigator_affiliation>
    <investigator_full_name>Department of Clinical Research and Innovation</investigator_full_name>
    <investigator_title>Departement of clinical research and innovation (drc)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

